News
-
-
-
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO
Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCO. Dupixent deviendrait la première thérapie ciblée pour la BPCO en Europe -
COMMUNIQUÉ DE PRESSE
Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPD
European Medicines Agency's CHMP recommends Dupixent for EU approval to treat uncontrolled COPD with raised blood eosinophils. If approved, it would be the first targeted therapy for COPD in the EU -
-
-
-
COMMUNIQUÉ DE PRESSE
Press Release: Sanofi completes acquisition of Inhibrx, Inc.
Sanofi completes acquisition of Inhibrx, Inc., adding SAR447537 to rare disease pipeline. Former Inhibrx shareholders receive $30.00 per share in cash and one contingent value right. Inhibrx Biosciences begins trading on NASDAQ as INXB -
-
